BG103334A - Antiviral vectors - Google Patents
Antiviral vectorsInfo
- Publication number
- BG103334A BG103334A BG103334A BG10333499A BG103334A BG 103334 A BG103334 A BG 103334A BG 103334 A BG103334 A BG 103334A BG 10333499 A BG10333499 A BG 10333499A BG 103334 A BG103334 A BG 103334A
- Authority
- BG
- Bulgaria
- Prior art keywords
- vector particles
- antiviral
- vectors
- antiviral vectors
- consitructed
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 2
- 241000713666 Lentivirus Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001566 pro-viral effect Effects 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
- 230000002463 transducing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mushroom Cultivation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9621680.9A GB9621680D0 (en) | 1996-10-17 | 1996-10-17 | Lentiviral vectors |
| PCT/GB1997/002858 WO1998017816A1 (en) | 1996-10-17 | 1997-10-17 | Lentiviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG103334A true BG103334A (en) | 2000-06-30 |
Family
ID=10801598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG103334A BG103334A (en) | 1996-10-17 | 1999-04-14 | Antiviral vectors |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6235522B1 (de) |
| EP (1) | EP0939827B1 (de) |
| JP (1) | JP2001502903A (de) |
| KR (1) | KR20000049250A (de) |
| CN (1) | CN1195864C (de) |
| AT (1) | ATE520783T1 (de) |
| AU (1) | AU737801B2 (de) |
| BG (1) | BG103334A (de) |
| CA (1) | CA2268271A1 (de) |
| CZ (1) | CZ137299A3 (de) |
| GB (2) | GB9621680D0 (de) |
| HU (1) | HUP0000442A3 (de) |
| IL (1) | IL128564A0 (de) |
| NO (1) | NO991742L (de) |
| NZ (1) | NZ334522A (de) |
| PL (1) | PL332876A1 (de) |
| WO (1) | WO1998017816A1 (de) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924123B2 (en) * | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| EP0981636B1 (de) | 1997-05-13 | 2005-03-23 | University Of North Carolina At Chapel Hill | Auf lentivirus basierende gentransfer-vektoren |
| FI112580B (fi) | 1997-06-27 | 2003-12-15 | Nokia Corp | Kutsunsiirron reititys peruspalvelukohtaisesti |
| CA2304983A1 (en) | 1997-09-24 | 1999-04-01 | The Regents Of The University Of California | Non-primate lentiviral vectors and packaging systems |
| US5994136A (en) * | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| AU4830899A (en) | 1998-06-24 | 2000-01-10 | Musc Foundation For Research Development | Tissue-specific and target rna-specific ribozymes |
| US6958226B1 (en) | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
| CA2365901A1 (en) | 1999-04-14 | 2000-10-19 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| AU778698B2 (en) | 1999-04-29 | 2004-12-16 | Miltenyi Biotec B.V. & Co. KG | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| EP1083230A1 (de) * | 1999-09-10 | 2001-03-14 | Academisch Medisch Centrum Amsterdam | Virale Replikons und von induzierenden Wirkstoffen abhängige Viren |
| AU1013601A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
| EP1702983A3 (de) | 2000-04-13 | 2007-01-10 | Medical University of South Carolina | Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisenseolinukleotide sowie Anwendungen dafür |
| ATE346925T1 (de) * | 2000-05-10 | 2006-12-15 | Sanofi Pasteur Ltd | Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen |
| US7101541B2 (en) | 2000-05-19 | 2006-09-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Utilization of non-viral sequences for minus-strand DNA transfer and gene reconstitution |
| WO2002034929A2 (en) * | 2000-10-20 | 2002-05-02 | Whitehead Institute For Biomedical Research | Expression vectors and uses thereof |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| US6712612B1 (en) | 2000-12-12 | 2004-03-30 | Genecure Llc | Safe and stable retroviral helper cell line and related compositions and methods |
| US20040235169A1 (en) * | 2001-04-20 | 2004-11-25 | Evans Ronald M. | Inducible expression of transfected genes |
| WO2002087341A1 (en) * | 2001-05-01 | 2002-11-07 | Genetix Pharmaceuticals, Inc. | Novel self-inactivating (sin) lentiviral vectors |
| WO2003012054A2 (en) * | 2001-08-02 | 2003-02-13 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
| CA2462628C (en) | 2001-10-02 | 2019-08-20 | Institut Clayton De La Recherche | Restricted expression lentiviral vectors |
| DK1504108T3 (da) | 2002-02-01 | 2013-06-10 | Oxford Biomedica Ltd | Lentivirusvektor |
| ATE369895T1 (de) | 2002-04-09 | 2007-09-15 | Sanofi Pasteur Ltd | Modifizierte cea nucleinsäure und expressionsvektoren |
| DK1499736T3 (da) * | 2002-04-26 | 2009-06-08 | Inst Nat Sante Rech Med | Forbedrede kimære glycoproteiner og pseudotypet lentovirale vektorer |
| DK1563069T3 (da) * | 2002-11-22 | 2012-07-23 | Inst Clayton De La Rech | Sammensætninger og systemer til genregulering |
| WO2005030927A2 (en) * | 2003-09-23 | 2005-04-07 | Uab Research Foundation | Methods and compositions for in vivo inflammation monitoring |
| US8562970B2 (en) * | 2003-10-08 | 2013-10-22 | Sanofi Pasteur Limited | Modified CEA/B7 vector |
| CN1980955A (zh) * | 2004-04-29 | 2007-06-13 | 北卡罗来纳-查佩尔山大学 | 增强细胞粘连特性的方法和组合物 |
| US20060292159A1 (en) * | 2005-06-08 | 2006-12-28 | Ranscht Barbara E | Methods for the inhibition of neovascularization and cancer metastasis |
| GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
| WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
| KR101554678B1 (ko) | 2012-10-19 | 2015-09-21 | 영남대학교 산학협력단 | 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도 |
| FI3889173T3 (fi) | 2013-02-15 | 2023-10-02 | Bioverativ Therapeutics Inc | Optimoitu tekijä viii:n geeni |
| CA2904802C (en) * | 2013-03-13 | 2021-03-30 | Zhong Li | Microvesicle and method for producing the same |
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
| EP3031923A1 (de) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| EP3443001B1 (de) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | Regulierte bioschaltkreissysteme |
| EP4652926A3 (de) | 2016-10-12 | 2026-03-18 | Bioverativ USA Inc. | Anti-c1s-antikörper und verfahren zur verwendung davon |
| KR102431830B1 (ko) | 2016-11-07 | 2022-08-16 | 주식회사 뉴라클사이언스 | 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법 |
| CN111344011B (zh) | 2017-06-27 | 2024-01-26 | 纽洛可科学有限公司 | 抗fam19a5抗体用于治疗纤维化的用途 |
| CA3067416A1 (en) | 2017-06-27 | 2019-01-03 | Neuracle Science Co., Ltd. | Use of anti-fam19a5 antibodies for treating cancers |
| JP6904616B2 (ja) | 2017-06-27 | 2021-07-21 | ニューラクル サイエンス カンパニー リミテッド | 緑内障治療のための配列相同性を有するファミリー、メンバーａ５抗体の用途 |
| JP7076059B2 (ja) | 2017-06-27 | 2022-05-27 | ニューラクル サイエンス カンパニー リミテッド | 抗ｆａｍ１９ａ５抗体及びその用途 |
| US11597917B2 (en) | 2017-07-06 | 2023-03-07 | The Medical College Of Wisconsin, Inc. | In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders |
| US11192944B2 (en) | 2017-10-11 | 2021-12-07 | Bioverativ Usa Inc. | Methods of inducing complement activity |
| AU2019215063B2 (en) | 2018-02-01 | 2025-10-16 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing Factor VIII |
| AU2019259798A1 (en) | 2018-04-24 | 2020-11-12 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain |
| US12239693B2 (en) | 2018-04-27 | 2025-03-04 | The Medical College Of Wisconsin, Inc. | Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders |
| KR20240056644A (ko) | 2018-05-10 | 2024-04-30 | 주식회사 뉴라클사이언스 | 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법 |
| CN119930818A (zh) | 2018-06-29 | 2025-05-06 | 爱必泰生物有限公司 | 抗l1cam抗体及其用途 |
| AU2019363368A1 (en) | 2018-10-16 | 2021-05-13 | Neuracle Science Co., Ltd. | Use of anti-FAM19A5 antibodies |
| CN113365650A (zh) | 2018-11-16 | 2021-09-07 | 新免疫技术有限公司 | 用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法 |
| BR112021010047A2 (pt) | 2018-12-06 | 2021-08-24 | Bioverativ Therapeutics Inc. | Uso de vetores lentivirais expressando o fator ix |
| KR20200071198A (ko) | 2018-12-10 | 2020-06-19 | 네오이뮨텍, 인코퍼레이티드 | Nrf2 발현 조절 기반 T 세포 항암면역치료법 |
| US20220144902A1 (en) * | 2018-12-25 | 2022-05-12 | National Center Of Neurology And Psychiatry | Method for inducing muscular cells using cells in spot urine |
| JP7239216B2 (ja) | 2018-12-27 | 2023-03-14 | ニューラクル サイエンス カンパニー リミテッド | 粥状硬化症を治療するための抗ｆａｍ１９ａ５抗体の使用 |
| CN113195533B (zh) | 2019-01-02 | 2024-04-26 | 纽洛可科学有限公司 | 抗序列相似家族19成员a5的抗体及其使用方法 |
| WO2021055801A1 (en) | 2019-09-18 | 2021-03-25 | The Medical College Of Wisconsin, Inc. | Improved alpha-galactosidase protein for enzyme replacement therapy (ert) and methods of use |
| US12403164B2 (en) | 2019-09-30 | 2025-09-02 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| US20230057939A1 (en) | 2020-01-13 | 2023-02-23 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and a bispecific antibody |
| EP4093752A2 (de) | 2020-01-22 | 2022-11-30 | Outpace Bio, Inc. | Chimäre polypeptide |
| WO2021151001A1 (en) | 2020-01-22 | 2021-07-29 | Outpace Bio, Inc. | Chimeric polypeptides |
| US20230210952A1 (en) | 2020-02-05 | 2023-07-06 | Washington University | Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells |
| KR20230074703A (ko) | 2020-06-24 | 2023-05-31 | 바이오버라티브 테라퓨틱스 인크. | 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법 |
| WO2022087453A1 (en) | 2020-10-22 | 2022-04-28 | Lyell Immunopharma, Inc. | Chimeric activation receptors |
| EP4232070A1 (de) | 2020-10-26 | 2023-08-30 | NeoImmuneTech, Inc. | Verfahren zur induktion von stammzellenmobilisierung |
| US20240101629A1 (en) | 2020-11-02 | 2024-03-28 | Neoimmunetech, Inc. | Use of interleukin-7 for the treatment of coronavirus |
| CN116615236A (zh) | 2020-11-05 | 2023-08-18 | 新免疫技术有限公司 | 用il-7蛋白和核苷酸疫苗的组合治疗肿瘤的方法 |
| WO2022251644A1 (en) | 2021-05-28 | 2022-12-01 | Lyell Immunopharma, Inc. | Nr4a3-deficient immune cells and uses thereof |
| JP2024520676A (ja) | 2021-06-02 | 2024-05-24 | ライエル・イミュノファーマ・インコーポレイテッド | Ｎｒ４ａ３欠損免疫細胞及びその使用 |
| EP4408874A1 (de) | 2021-09-30 | 2024-08-07 | Bioverativ Therapeutics Inc. | Faktor viii polypeptid kodierende nukleinsäuren mit verminderter immunogenität |
| KR20240115979A (ko) | 2021-11-08 | 2024-07-26 | 프로젠토스 테라퓨틱스, 인크. | 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도 |
| EP4456907A1 (de) | 2021-12-30 | 2024-11-06 | NeoImmuneTech, Inc. | Verfahren zur behandlung eines tumors mit einer kombination aus il-7-protein und vegf-antagonist |
| CN119866224A (zh) | 2022-07-28 | 2025-04-22 | 加拿大干细胞技术公司 | 编码连接抗原的多核苷酸以及其用途 |
| KR20250089492A (ko) | 2022-11-07 | 2025-06-18 | 네오이뮨텍, 인코퍼레이티드 | 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법 |
| KR20260033048A (ko) | 2023-07-03 | 2026-03-10 | 네오이뮨텍, 인코퍼레이티드 | 이종이합체 fc 분자 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604114A (en) * | 1986-05-20 | 1997-02-18 | Dana-Farber Cancer Institute | Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use |
| WO1992021750A1 (en) | 1991-05-29 | 1992-12-10 | THE UNITED STATES OF AMERICA, represented by THE SCRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | Eukaryotic expression vectors with regulation of rna processing |
| AU2419595A (en) * | 1994-05-10 | 1995-11-29 | Hisamitsu Pharmaceutical Co., Inc. | Recombinant human immunodeficiency virus vector and process for producing the same |
| WO1995032300A1 (en) | 1994-05-23 | 1995-11-30 | University Of Medicine & Dentistry Of New Jersey | Selective biological destruction of tumor cells |
| US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| DE69627644T2 (de) | 1995-03-09 | 2004-02-19 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie |
| GB9510272D0 (en) | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
| WO1997048277A1 (en) * | 1996-06-20 | 1997-12-24 | The Salk Institute For Biological Studies | Modular assembly retroviral vectors and uses thereof |
-
1996
- 1996-10-17 GB GBGB9621680.9A patent/GB9621680D0/en active Pending
-
1997
- 1997-10-17 CA CA002268271A patent/CA2268271A1/en not_active Abandoned
- 1997-10-17 NZ NZ334522A patent/NZ334522A/en not_active IP Right Cessation
- 1997-10-17 CZ CZ991372A patent/CZ137299A3/cs unknown
- 1997-10-17 AT AT97909437T patent/ATE520783T1/de not_active IP Right Cessation
- 1997-10-17 IL IL12856497A patent/IL128564A0/xx unknown
- 1997-10-17 GB GB9903117A patent/GB2331522B/en not_active Expired - Lifetime
- 1997-10-17 HU HU0000442A patent/HUP0000442A3/hu unknown
- 1997-10-17 PL PL97332876A patent/PL332876A1/xx unknown
- 1997-10-17 KR KR1019990703355A patent/KR20000049250A/ko not_active Ceased
- 1997-10-17 EP EP97909437A patent/EP0939827B1/de not_active Expired - Lifetime
- 1997-10-17 CN CNB971988838A patent/CN1195864C/zh not_active Expired - Lifetime
- 1997-10-17 US US09/284,011 patent/US6235522B1/en not_active Expired - Lifetime
- 1997-10-17 AU AU47123/97A patent/AU737801B2/en not_active Expired
- 1997-10-17 JP JP10519087A patent/JP2001502903A/ja not_active Ceased
- 1997-10-17 WO PCT/GB1997/002858 patent/WO1998017816A1/en not_active Ceased
-
1999
- 1999-04-13 NO NO991742A patent/NO991742L/no not_active Application Discontinuation
- 1999-04-14 BG BG103334A patent/BG103334A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL332876A1 (en) | 1999-10-25 |
| HUP0000442A3 (en) | 2001-09-28 |
| GB2331522A (en) | 1999-05-26 |
| CN1234075A (zh) | 1999-11-03 |
| AU4712397A (en) | 1998-05-15 |
| CZ137299A3 (cs) | 1999-07-14 |
| GB9903117D0 (en) | 1999-04-07 |
| GB2331522B (en) | 2001-05-23 |
| EP0939827A1 (de) | 1999-09-08 |
| NO991742D0 (no) | 1999-04-13 |
| GB9621680D0 (en) | 1996-12-11 |
| HUP0000442A2 (hu) | 2000-06-28 |
| KR20000049250A (ko) | 2000-07-25 |
| CA2268271A1 (en) | 1998-04-30 |
| US6235522B1 (en) | 2001-05-22 |
| IL128564A0 (en) | 2000-01-31 |
| NZ334522A (en) | 2001-11-30 |
| NO991742L (no) | 1999-04-13 |
| WO1998017816A1 (en) | 1998-04-30 |
| CN1195864C (zh) | 2005-04-06 |
| JP2001502903A (ja) | 2001-03-06 |
| AU737801B2 (en) | 2001-08-30 |
| HK1018481A1 (en) | 1999-12-24 |
| ATE520783T1 (de) | 2011-09-15 |
| EP0939827B1 (de) | 2011-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2331522A (en) | Lentiviral vectors | |
| BG103397A (en) | Retroviral vectors | |
| BG102048A (en) | Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors | |
| AU4880093A (en) | Retrovirus from the HIV group and its use | |
| CA2328404A1 (en) | Novel lentiviral packaging cells | |
| EP0887427A3 (de) | Amplifizierung und Detektion von HIV-1 und/oder HIV-2 | |
| CA2011878A1 (en) | Immunogenic regions on the e7 protein of human papillomavirus type 16 | |
| AU3636189A (en) | Hiv-2 virus variants | |
| EP0334368A3 (de) | Herstellung von 2',3'-Dideoxy-2',3'-didehydronucleosiden | |
| AU4320689A (en) | Expression of retrovirus gag protein in eukaryotic cells | |
| DK631688D0 (da) | 2',3'-dideoxy-2'-fluornucleosider, fremstillingen deraf samt praeparater indeholdende samme | |
| EP0759471A4 (de) | Rekombinanter vektor bestehend aus dem menschlichen immunschwäche-virus und verfahren zu seiner herstellung | |
| FI940867A0 (fi) | Ilmentämisrakenteita, jotka sisältävät HIV:iä estäviä antisense- ja muita nukleotidisekvenssejä, retrovirusvektoreita ja näitä sisältäviä yhdistelmäretroviruksia | |
| EP1262554A3 (de) | Defekte verpackende nicht-Oncoviren Vektoren aus Mpmv und Hiv | |
| AU3258295A (en) | Retroviral vector hybrids and the use thereof for gene transfer | |
| DK0801575T3 (da) | Retrovirale vektorer til ekspression i embryoniske celler | |
| AU5686196A (en) | Use of an "immunodeficiency-virus suppressing lymphokine (ISL)" to inhibit the replication of viruses, in particular of retroviruses | |
| CA2282394A1 (en) | Retroviral vectors, methods for their preparation and their use for gene transfer into cd4-positive cells | |
| WO1994020621A3 (en) | Proteinaceous particles containing retroviral element | |
| AU7289587A (en) | Immunosuppressive factor from human immunodeficiency virus (hiv) or hiv infected cells or cell lines, its use, corresponding antibodies and their use | |
| CA2141951A1 (en) | Inhibition of retrovirus infection | |
| WO1999034006A3 (en) | A method for the positive selection of cd4+ t-lymphocytes transduced with anti-hiv genes | |
| AU1711088A (en) | Hiv related human retrovirus strain with cloned nucleotide sequence and applications thereof | |
| AU4767093A (en) | Peptides derived from an immunosuppressive region in the retroviral genome | |
| AU1275095A (en) | Antiviral composition of viral protein trans-dominant variants |